Twelve firms set USD 56.38 consensus target for Immunocore stock

Transcript Daily reported on October 17, 2026 that twelve research firms put Immunocore's average one-year target at USD 56.38, 91.77 percent above the stock's closing level. The target gives the market's current estimate a clear numerical distance from the latest completed session.

November date sets the next test

MarketBeat estimated on October 16, 2026 that Immunocore would report third-quarter results on November 5, 2026, before the market opens. The same page lists consensus revenue of USD 152.86 million and a consensus loss of USD 0.1204 per share for that period.

Range and turnover define the setup

Immunocore closed at USD 29.40 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 0.27 percent from the prior close of USD 29.48. The session volume was 924,921 shares, versus an average volume of 429,860 shares, making the latest turnover 115.18 percent higher than that average.

The one-year range was USD 27.50 to USD 40.72 as of October 16, 2026. The closing price stood 6.91 percent above the low and 27.80 percent below the high, keeping the stock nearer its lower boundary than its upper one.

Valuation and peers

Immunocore had a market capitalization of USD 1.5 billion and a price-to-earnings ratio of -154.49 as of October 16, 2026. The company paid no trailing dividend, while the USD 56.38 consensus target from twelve firms remained the most visible valuation reference.

Comparison with peers

Immunocore (NASDAQ, USD): down 0.27 percent, P/E -154.49, market capitalization USD 1.5 billion.

Rigel Pharmaceuticals (NASDAQ, USD): down 2.71 percent, P/E 2.82, market capitalization USD 858.7 million.

Sera Prognostics (NASDAQ, USD): up 1.48 percent, P/E -3.07, market capitalization USD 79.3 million.

What the next date puts in view

The November 5, 2026 reporting date will put the USD 152.86 million revenue consensus alongside Immunocore's latest commercial and development updates. The company develops T-cell receptor therapies, with KIMMTRAK as its lead commercial product.

Stock position in dollars

The latest completed Nasdaq session left Immunocore at USD 29.40, with the stock 6.91 percent above its one-year low and below its one-year high. The price-to-earnings ratio remained negative, so the November revenue outlook and the consensus target provide the more concrete reference points.

Market context: Market report Nasdaq Composite.

More news and analyses on Immunocore stock